Monitoring Milestones in Patients With Chronic Myeloid Leukemia - PowerPoint PPT Presentation

Loading...

PPT – Monitoring Milestones in Patients With Chronic Myeloid Leukemia PowerPoint presentation | free to download - id: 7537dd-NGZjZ



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Monitoring Milestones in Patients With Chronic Myeloid Leukemia

Description:

Monitoring Milestones in Patients With Chronic Myeloid Leukemia Cytogenetic Relapse at 18 months Best Molecular Response Thank you for participating in this activity. – PowerPoint PPT presentation

Number of Views:156
Avg rating:3.0/5.0
Slides: 37
Provided by: SOluku
Learn more at: http://img.medscape.com
Category:

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Monitoring Milestones in Patients With Chronic Myeloid Leukemia


1
Monitoring Milestones in Patients With Chronic
Myeloid Leukemia
2
Activity Goal
3
Treatment Milestones
4
Workup Patient Newly Diagnosed in Chronic Phase
5
Definition of Response in CML
6
Definition of Response in CML (cont)
7
Response Milestones Frontline Imatinib in
Chronic Phase CML
8
Faster Responses With Nilotinib and Dasatinib
9
Prediction of Outcome Based on the 3-month Time
Point
10
BCR-ABL/ABL lt 10 by IS at 3 Months Predicts
Outcome
11
What Are the Options When the 3-month Time Point
Has NOT Been Reached?
12
At 3 Months, BCR-ABL of 10 IS Identifies
High-Risk Patients
13
Retrospective Analysis of CML Study IV MMR and
CCyR at 3 Months
14
Considerations for the 3-month Time Point
15
Conclusions
16
Monitoring at the 6-Month Time Point
17
Monitoring at the 6-month Time Point
18
Rise and Fall of BCR-ABL Transcript Levels With
Imatinib Dosing
19
Retrospective Analysis of CML Study IV MMR and
CCyR at 6 Months
20
Monitoring at the 12-Month Time Point
21
12-month Follow-up
22
12-month Follow-up (cont)
23
12-month Follow-up (cont)
24
12-month Follow-up Relapse
25
Algorithm for Modulating Risk Factors
26
BCR-ABL KD Mutations Before and After Imatinib
Therapy
27
Conclusions
28
Monitoring Patients at the 18-Month Time Point
29
Monitoring at the 18-month Time Point
30
Event-free Survival by Response
31
Monitoring at the 18-month Time Point
32
Treating Patients With Mutations in the Second
Linea,b
33
Results With Second-/Third-Generation TKI After
Imatinib Failure/Resistance
34
Cytogenetic Relapse at 18 months
35
Best Molecular Response
36
Thank you for participating in this activity.
About PowerShow.com